Mieloma Multipel: Laporan Kasus

Mulat Muliasih

Sari


Mieloma multipel (MM) adalah keganasan yang ditandai dengan proliferasi klon tunggal sel plasma yang berasal dari sel B di sumsum tulang. MM menempati keganasan hematologi nomor dua pada usia dewasa dan merupakan kanker hematologi dengan keterlibatan sistem skeletal terbanyak. Laporan kasus ini bertujuan untuk menjelaskan diagnosis MM pada pasien dengan keterlibatan sistem skeletal. Seorang pria berusia 50 tahun datang dengan keluhan utama nyeri punggung bawah, disertai penurunan berat badan dan batuk lama. Gejala yang tidak khas menyebabkan penegakan diagnosis MM baru ditegakkan dalam waktu hampir dua bulan. Hasil laboratorium didapatkan anemia, peningkatan ureum dan kreatinin, peningkatan sel plasma, dan gamma globulin yang tinggi pada elektroforesis protein serum. Hasil survei tulang didapatkan osteolitik pada parietal dan skapula serta fraktur kompresi di vertebra lumbal. Nyeri radikular pada MM merupakan komplikasi yang paling sering dikeluhkan dalam praktik klinis. Keluhan nyeri radikular pada pasien dewasa harus diwaspadai adanya keterlibatan MM. Diagnosis dan intervensi dini dapat mencegah progresifitas penyakit lebih lanjut.


Kata Kunci


Diagnosis; Mieloma Multipel; Nyeri Radikular

Teks Lengkap:

PDF

Referensi


Abduh, M.S. (2024). An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities. Saudi J Biol Sci, 31(2):103920.

Ali, M.N. (2020). Multiple Myeloma: An Uncommon Presentation of a Common Neurological Problem. J Nephrol Sci, 2(1):1-4.

Anderson, K.C. (2016). Progress and Paradigms in Multiple Myeloma. Clin Cancer Res, 22:5419-5427.

Bakta, I. M. (2019). Mieloma multipel: aspek patogenesis molekuler. Jurnal Penyakit Dalam Udayana, Vol 3 No 1:1-7.

Bergagsel, P.L., Kuehl, W.M. (2005). Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma. J Clin Oncol, 23:6333-6338.

Chesi, M., Bergsagel P.L. (2013). Molecular pathogenesis of multiple myeloma:basic and clinical updates. Int J Hematol, 97:313-323.

Greenspan, A. (2000). Malignant bone tumors II. In: Greenspan A, editor. Orthopedic radiology: a practical approach. 3rd ed. Philadelphia, Pa: Lippincott Williams& Wilkins, p. 697-700.

Hussain, A., et al. (2019). Laboratory Features of Newly Diagnosed Multiple Myeloma Patients. Cureus, 22;11(5):e4716.

Kaseb, H., et al. (2022). Plasma Cell Cancer. [Updated 2022 Sep 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507913/

Kazandjian, D. (2016). Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol, 43(6):676-681.

Ludwig, H., et al. (2014). International Myeloma Working Group recommendations for global myeloma care. Leukemia, 28(5):981-92.

Mikhael, et al. (2023). Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations. The American Journal of Medicine, Vol 136, Issue 1, 33 – 41.

Mousavi, S.E., et al. (2025). Epidemiology, socioeconomic correlates, and trend projections of multiple myeloma in Asia over 2020–2040. Heliyon, Vol 11, Issue 9.

Nwabuko, O.C. (2023). Multiple Myeloma: Risk Factors, Pathogenesis and Relationship with Anti-myeloma Therapies. J Explor Res Pharmacol, 8(1):57-65. doi: 10.14218/JERP.2022.00059.

Padala, S.A., et al. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel), 9(1):3. doi: 10.3390/medsci9010003.

Pantanowitz, L., Tranovich, V., Ballesteros, E., (2008). Flaming plasma cells. Archives of Pathology and Laboratory Medicine, 125(10): 1394–5. Retrieved from: http://arpa.allenpress.com on Juni 14th, 2008.

Rajabli, et al. (2013). Epidemiology of Leukemia and Multiple Myeloma in Golestan, Iran. Asian Pacific journal of cancer prevention : APJCP, 14: 2333-2336.

Rao, G., et al. (2006). Multiple myeloma of the cervical spine: treatment strategies for pain and spinal instability. J Neurosurg Spine, 5:140-5.

Rajkumar, S.V. (2022). Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol, 97(8):1086-1107. doi: 10.1002/ajh.26590.

Silva C., el al . (2021). Light-Chain Multiple Myeloma: A Diagnostic Challenge. Cureus, 13(10):e19131.

Shuji, U., et al. (2018). The Current Situation of Multiple Myeloma Treatment in Japan: A Cross-Sectional Analysis Based on Health Insurance Claims Data. Blood, Vol 132, Supplement 1.

Terpo E., et al. (2018). Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer Journal, 8:1-12.

Therneau, T.M., et al. (2012). Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc, 87:1071–9.

Yusuf, A.F.N., Rizki, M. (2023). Multiple myeloma: mengenali awitan hingga prognosis. Jurnal Medika Hutama, Vol 04 No 02.




DOI: https://doi.org/10.33024/jikk.v12i12.23953

Refbacks

  • Saat ini tidak ada refbacks.


##submission.copyrightStatement##

##submission.license.cc.by-nc4.footer##

Pendidikan Dokter Universitas Malahayati Lampung



Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.